Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
Shares of Editas Medicine, Inc. (NASDAQ:EDIT – Get Rating) have been given an average rating of “Hold” by the fourteen brokerages that are covering the firm, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a sell recommendation, seven have given a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $15.46.
Several equities analysts have recently issued reports on the stock. SVB Leerink dropped their price target on shares of Editas Medicine from $14.00 to $7.00 and set a “market perform” rating for the company in a research note on Thursday, November 17th. Credit Suisse Group reaffirmed a “neutral” rating and issued a $13.00 price objective on shares of Editas Medicine in a research note on Tuesday, December 6th. Evercore ISI dropped their price target on shares of Editas Medicine to $8.00 in a research report on Monday, November 21st. Truist Financial lowered their price objective on shares of Editas Medicine from $80.00 to $35.00 and set a “buy” rating on the stock in a research report on Friday, November 18th. Finally, Citigroup started coverage on shares of Editas Medicine in a research note on Tuesday, December 13th. They set a “neutral” rating and a $11.00 price objective for the company.
Institutional Trading of Editas Medicine
Several institutional investors and hedge funds have recently bought and sold shares of EDIT. Continental Investors Services Inc. acquired a new stake in shares of Editas Medicine in the third quarter worth $698,000. Bank of New York Mellon Corp raised its position in shares of Editas Medicine by 8.7% during the 3rd quarter. Bank of New York Mellon Corp now owns 253,291 shares of the company’s stock valued at $3,100,000 after acquiring an additional 20,327 shares during the last quarter. IHT Wealth Management LLC bought a new stake in shares of Editas Medicine during the 3rd quarter valued at $165,000. B. Riley Wealth Advisors Inc. acquired a new position in Editas Medicine in the 3rd quarter worth $132,000. Finally, Alpha Paradigm Partners LLC acquired a new position in shares of Editas Medicine during the 3rd quarter worth about $348,000. Institutional investors and hedge funds own 69.67% of the company’s stock.
Editas Medicine Stock Down 1.2 %
Shares of EDIT stock opened at $8.87 on Monday. The firm has a market capitalization of $609.93 million, a price-to-earnings ratio of -3.02 and a beta of 1.88. Editas Medicine has a 12-month low of $8.21 and a 12-month high of $28.74. The firm has a fifty day moving average of $10.60 and a 200-day moving average of $13.14.
Editas Medicine (NASDAQ:EDIT – Get Rating) last released its quarterly earnings data on Wednesday, November 2nd. The company reported ($0.81) earnings per share for the quarter, topping the consensus estimate of ($0.87) by $0.06. Editas Medicine had a negative net margin of 784.32% and a negative return on equity of 41.33%. The company had revenue of $0.04 million for the quarter, compared to analyst estimates of $5.86 million. Research analysts expect that Editas Medicine will post -3.21 earnings per share for the current year.
About Editas Medicine
(Get Rating)
Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness.
Further Reading
- Get a free copy of the StockNews.com research report on Editas Medicine (EDIT)
- MarketBeat: Week in Review 12/26 – 12/30
- The Dogs Of Tech: It’s Time For A Bite Of These Stocks
- Does This Acquisition Make Microsoft a Bear Market Buy?
- Is Kintara Therapeutics A Hidden Gem?
- Should You Warm up to Generac Stock for the Winter?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Editas Medicine, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Editas Medicine wasn’t on the list.
While Editas Medicine currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Enter your email address below and we’ll send you MarketBeat’s guide to investing in 5G and which 5G stocks show the most promise.
Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat’s trending stocks report.
Identify stocks that meet your criteria using seven unique stock screeners. See what’s happening in the market right now with MarketBeat’s real-time news feed. Export data to Excel for your own analysis.
As Featured By:
326 E 8th St #105, Sioux Falls, SD 57103
contact@marketbeat.com
(844) 978-6257
© American Consumer News, LLC dba MarketBeat® 2010-2023. All rights reserved.
© 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer.
